JBC Oz Biosciences

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M112029200 on January 28, 2002

J. Biol. Chem., Vol. 277, Issue 15, 13331-13337, April 12, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/15/13331    most recent
M112029200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aoukaty, A.
Right arrow Articles by Tan, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aoukaty, A.
Right arrow Articles by Tan, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Association of the X-linked Lymphoproliferative Disease Gene Product SAP/SH2D1A with 2B4, a Natural Killer Cell-activating Molecule, Is Dependent on Phosphoinositide 3-Kinase*

Ala AoukatyDagger and Rusung Tan§

From the Department of Pathology and Laboratory Medicine, British Columbia's Children's Hospital and University of British Columbia, 4480 Oak Street, Vancouver, British Columbia V6H 3V4, Canada

Received for publication, December 17, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Natural killer (NK) cells express an activating receptor, 2B4, that enhances cellular cytotoxicity. Upon NK cell activation by ligation of 2B4, the intracellular domain of 2B4 associates with the X-linked lymphoproliferative disease (XLP) gene product, signaling lymphocytic activation molecule-associated protein/SH2D1A (SAP/SH2D1A). Defective intracellular association of 2B4 with mutated SAP/SH2D1A is likely to underlie the defects in cytotoxicity observed in NK cells from patients with XLP. We report here a role for phosphoinositide 3-kinase (PI3K) in the recruitment and association of SAP/SH2D1A to 2B4 in human NK cells. The activation of normal NK cells by ligation of 2B4 leads to the phosphorylation of 2B4, recruitment of SAP/SH2D1A, and association of the p85 regulatory subunit of PI3K. The inhibition of PI3K enzymatic activity with either wortmannin or LY294002 prior to 2B4 ligation does not alter the association of 2B4 with the p85 subunit but prevents the recruitment of SAP/SH2D1A to 2B4. In addition, PI3K inhibitors significantly diminish the cytotoxic function of primary NK cells. This observed inhibition of cytotoxicity, present in normal NK cells, was less apparent or absent in NK cells derived from a patient with XLP. These data indicate that the cytotoxicity of activated NK cells is mediated by the association of 2B4 and SAP/SH2D1A, and that this association is dependent upon the activity of PI3K.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Natural killer (NK)1 cells are an integral component of the antiviral immune response acting to limit viral replication through both cellular cytotoxic mechanisms and the secretion of cytokines (1, 2). A large number of activating and inhibitory receptors are expressed on the surface of NK cells, and there is a general agreement that the effector function of NK cells is determined by a balance of positive and negative intracellular signals (3, 4). An important activating receptor of NK cells is 2B4, a member of the CD2 subset of the immunoglobulin superfamily (5, 6). Upon 2B4 activation by a natural ligand, CD48, or with a monoclonal antibody, NK cells are induced to augment their cytotoxicity, secrete interferon-gamma , and increase calcium flux, phosphoinositol turnover, and perforin degranulation. (7-9).

The cytoplasmic tail of 2B4 contains four tyrosine-based motifs that allow for phosphorylation and subsequent binding by molecules containing src-homology 2 (SH2) domains (6, 10, 11). Thus, following stimulation, human 2B4 has been shown to be phosphorylated (12, 13) and associate with a number of SH2 proteins including the SHP-1 and SHP-2 phosphatases (12, 14, 15) and p62dok (Dok1) (16) as well as with the linker for the activation of T-lymphocytes (LAT), an adaptor protein that acts as a substrate for SH2 proteins (17). In addition, 2B4 associates with signaling lymphocytic activation molecule-associated protein/SH2D1A (SAP/SH2D1A), an adaptor molecule containing a single SH2 domain (18).

SAP/SH2D1A is expressed in both NK cells and T-lymphocytes, and the mutations of SAP/SH2D1A are associated with the immunodeficiency syndrome, X-linked lymphoproliferative disease (XLP) (19-21). Consistent with the expression of SAP/SH2D1A in NK cells and its intracellular association with 2B4, XLP patients manifest defects in NK cytotoxic function, particularly following 2B4 activation (18, 22-24). However, the detailed intracellular mechanisms by which SAP/SH2D1A influences 2B4 signaling and NK function are unclear, and in particular, the involvement of phosphoinositide 3-kinase (PI3K) in 2B4-mediated cytotoxicity is unknown.

Class I PI3K, the isoform most linked to lymphocytes, comprises both a catalytic (p110alpha , beta , gamma , or delta ) and a regulatory (p85alpha , p85beta , p101, or p55 gamma ) subunit (25, 26). In the case of tyrosine-phosphorylated membrane receptors such as 2B4, PI3K activation begins with the formation of a high affinity interaction between SH2 domains of either p85alpha or p85beta and tyrosine-phosphorylated cytoplasmic domains of the membrane receptor. The association of the p85 subunit recruits the p110 catalytic subunit, which can phosphorylate the D-3 position of the inositol ring of phosphoinositol lipids. The phosphorylated inositol lipids and other metabolites including phosphatidylinositol 3,4-biphosphate are termed 3'-phosphoinositides and act as second messengers in signal transduction. A role for PI3K and 3'-phosphoinositides is suggested because PI3K is known to participate in antibody-dependent cellular cytotoxicity of NK cells (27, 28), and inhibition of PI3K activity has been shown to decrease the cellular cytotoxicity of an NK cell line, NK92 (29).

In this study, we investigated the role of PI3K in the downstream signaling events of 2B4 following the activation of primary human NK cells. We show that the p85 regulatory subunit of PI3K associates with 2B4, and that the association of 2B4 with SAP/SH2D1A is abrogated by the inhibition of PI3K enzymatic activity. We also provide evidence that PI3K activity induced by 2B4 stimulation is absent in NK cells expressing mutated SAP/SH2D1A. Finally, we show that PI3K inhibitors diminish the cytotoxicity of NK cells obtained from healthy individuals but have little or no effect on the cytotoxicity of NK cells from an XLP patient.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Antibodies and Reagents-- Polyclonal antiserum to human SAP/SH2D1A was produced by immunizing rabbits with a C-terminal peptide (GTTGIREDPDVCLKAP) coupled to keyhole limpet hemocyanin (ImmuneChem Pharmaceuticals, Vancouver, British Columbia, Canada). Antibodies used included anti-2B4 (mAb C1.7, Biodesign International, Saco, ME), anti-p85 (BD Transduction Laboratories, Mississauga, Ontario, Canada), antiphosphotyrosine (4G10, Upstate Biotechnology, Lake Placid, NJ), anti-CD3 fluorescein isothiocyanate, and anti-CD56 PE (BD PharMingen, Mississauga, Ontario, Canada). Chemical reagents used were protease inhibitors mixture, wortmannin, LY294002 (Sigma) and PD98059, protein kinase C inhibitor (19-27), and Lck inhibitor PP2 (Calbiochem).

Natural Killer Cells-- The study was approved by the University of British Columbia Clinical Research Ethics Board, and informed consent was obtained from all subjects prior to blood collection. NK cells were selected from peripheral blood using RosetteSep (StemCell Technologies, Vancouver, British Columbia, Canada) containing antibodies to CD3, CD36, CD4, CD66b, CD19, and glycophorin A followed by Ficoll density gradient centrifugation. Cells were cultured in complete medium (CM) consisting of RPMI 1640 medium supplemented with 10% human serum, 10 units/ml penicillin, 100 µg/ml streptomycin, 1 mM L-glutamine, 1% nonessential amino acids, 5 × 10-5 M 2-mercaptoethanol, and 1000 IU/ml IL-2 (Teceleukin, Roche Molecular Biochemicals). These cells were used for all experiments and represent an IL-2-activated NK or lymphokine-activated killer cell phenotype. Prior to experiments, NK cells were rested for 6 h in AIM-V serum-free medium (Invitrogen). For inhibition experiments, chemical inhibitors (100 nM wortmannin, 100 µM LY294002, 25 µM PD98059, 100 µM protein kinase C inhibitor (residues 19-27 of sequence RFARKGALRQKNV), or 100 µM PP2) were added for 30 min at 37 °C. The concentrations for wortmannin and LY294002 were determined by dose response experiments (data not shown). For activation, NK cells were incubated for 5 min with mAb C1.7 and IL-2 (100 IU/ml).

Cytotoxicity Assays-- NK cells were prepared as described above and used in either an inactivated (CM alone) or activated (CM with anti-2B4 and IL-2) state as effector cells. The target cells were either the NK-sensitive chronic myelogenous leukemia cell line, K562 (ATCC, Manassas, VA), or the NK-resistant lymphokine-activated killer-sensitive Burkitt's lymphoma cell line, Raji (ATCC, Manassas, VA). Target cells were maintained in RPMI 1640 medium with 10% fetal calf serum and labeled with 51Cr for 1 h. The effector to target ratio was adjusted to 20:1 and/or 10:1 in a total volume of 200 µl. The cells were incubated for 4 h at 37 °C, and 100 µl of supernatant was removed from each well for gamma -radiation counting. Specific lysis was calculated as described previously (23).

Western Blots and Immunoprecipitations-- NK cells (5 × 106 cells) were incubated for 30 min at 4 °C with gentle agitation in lysis buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.2 mM sodium vanadate, 0.2 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 0.5% Nonidet P-40, and protease inhibitors mixture). The preparation was centrifuged at 14,000 × g at 4 °C for 15 min, and the lysate was precleared by incubation with protein A/G-agarose at 4 °C for 15 min to reduce the nonspecific binding of proteins to agarose beads. The protein concentration of the lysates was measured by the Bradford method, and equal amounts were used in Western blots or immunoprecipitates. For immunoprecipitates, the lysates were incubated overnight at 4 °C with a 1:100 dilution of the relevant antibody. The immune complexes were collected by the addition of protein A/G-agarose, and the pellet was washed three times in immunoprecipitated buffer before suspension in SDS sample buffer. Proteins were separated by SDS-PAGE, transferred onto polyvinylidene difluoride membranes, and blocked with 5% skim milk in Tris-buffered saline containing 0.05% Tween 20 with the exception of tyrosine phosphorylation experiments where 1% bovine serum albumin was added to the Tris-buffered saline containing 0.05% Tween 20. The membranes were incubated with primary antibody in blocking buffer overnight at 4 °C and then with secondary antibody for 2 h at room temperature before detection using either a color development method (Bio-Rad) or ECL using SuperSignal WestPico substrate (Pierce). For all assays, wide range molecular weight standards were used (Bio-Rad).

Phosphatidylinositol Kinase Assay-- PI3K assays were performed as described previously (30). NK cells were either left intact or pretreated with 100 nM wortmannin as described earlier and then were incubated in CM alone or CM with mAb C1.7 and IL-2 (100 IU/ml) for 5 min. Cell lysates were immunoprecipitated with mAb C1.7, and immunocomplexes were washed first with buffer containing 137 mM NaCl, 20 mM Tris base, pH 7.5, 1 mM CaCl2, 1 mM MgCl2, 0.1 mM sodium orthovanadate, and 1% Nonidet P-40 and then with buffer containing 0.5 M LiCl, 100 mM Tris-HCl, pH 7.5, and 1 mM sodium orthovanadate and finally with Tris/NaCl/EDTA buffer containing 0.1 mM sodium orthovanadate. The protein complexes were mixed with 50 µl of Tris/NaCl/EDTA buffer, 10 µl (20 µg) of phosphatidylinositol 4,5-bisphosphate (Sigma), and 10 µl of 100 mM MgCl2. The reaction was started by the addition of 30 µCi/sample of [gamma -32P]ATP (Amersham Biosciences) and incubated for 10 min at 25 °C. MgCl2 (20 mM) was then added to this mixture for an additional 15 min. The reaction was stopped by the addition of 20 µl of 6 N HCl and 160 µl of CHCl3:MeOH (1:1). The organic phase was separated from the chloroform layer, and 50 µl was spotted on thin layer chromatography aluminum Silica Gel 60 F254 precoated sheets (Sigma). Thin layer chromatography plates were developed and resolved in CHCl3:MeOH:H2O:NH4OH (60:47:11.3:2), left to dry, and phosphatidylinositol 1,4,5-trisphosphate products were visualized by autoradiography.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

NK Cell Activation by Anti-2B4 Results in 2B4 Phosphorylation and the Recruitment of SAP/SH2D1A in Normal but Not XLP NK Cells-- Previous reports indicate that the activation of NK cell lines by the ligation of 2B4 is followed by 2B4 phosphorylation and the recruitment of SAP/SH2D1A (12, 17). Using NK cells from healthy individuals, we found that activation of primary NK cells with an antibody to 2B4 (31) results in 2B4 phosphorylation within 2 min of stimulation (Fig. 1A) and the recruitment of SAP/SH2D1A (Fig. 1B). The association of 2B4 and SAP/SH2D1A is present following ligation with anti-2B4 alone but is significantly enhanced when IL-2 is present, suggesting a synergistic interaction between 2B4 and IL-2 and also implying that downstream pathways of IL-2 signaling are important for the recruitment of SAP/SH2D1A (Fig. 1B). The association between 2B4 and SAP/SH2D1A begins at 5 min following NK activation and persists at least 20 min (Fig. 1C). In contrast, cells from an XLP patient who carries an inactivating arginine to leucine (R55L) mutation of SAP/SH2D1A (32) failed to recruit SAP/SH2D1A to 2B4 following activation (Fig. 1D). The lack of association between 2B4 and SAP/SH2D1A was not because of an absolute lack of SAP/SH2D1A expression in mutated cells, although there was a decreased level of expression seen (Fig. 1E).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 1.   NK cell activation by anti-2B4 results in 2B4 phosphorylation and the recruitment of SAP/SH2D1A in normal but not XLP NK cells. A, phosphorylation of 2B4 following activation. NK cells were incubated at 37 °C in CM alone (lane 1), CM with mouse IgG (lane 2), or CM with mAb C1.7 and IL-2 (lane 3). Cell lysates were collected after 2 min, immunoprecipitated (IP) with anti-2B4, and immunoblotted (IB) with antiphosphotyrosine. B, SAP/SH2D1A associates maximally with 2B4 following stimulation with anti-2B4 and IL-2. NK cells were incubated at 37 °C for 5 min under the indicated conditions. Cell lysates were immunoprecipitated with anti-SAP/SH2D1A and immunoblotted with mAb C1.7. C, time course of SAP/SH2D1A-2B4 association. NK cells were incubated at 37 °C in CM (lane 1), or in CM with mAb C1.7 and IL-2 (lanes 2-6, respectively) for indicated times before cell lysis. Cell lysates were immunoprecipitated with anti-2B4 and immunoblotted with anti-SAP/SH2D1A. D, mutated SAP/SH2D1A does not associate with 2B4. NK cell lysates from normal controls or an XLP patient were immunoprecipitated with anti-2B4 and immunoblotted with anti-SAP/SH2D1A. E, expression of SAP/SH2D1A in normal and XLP NK cells. Cell lysates from were resolved by SDS-PAGE and immunoblotted with anti-SAP/SH2D1A. WB, Western blot. The molecular masses are indicated by the markers on the left.

2B4 Associates with the p85 Subunit of PI3K and Activated PI3K Recruit SAP/SH2D1A to 2B4-- Because PI3K has been previously implicated in both NK cytotoxicity (29) and chemotaxis (30, 33), we investigated whether PI3K associates with 2B4 in activated NK cells. The PI3K isoform in lymphocytes consists of a regulatory subunit p85, which contains two SH2 domains, and a catalytic subunit p110, which functions as a lipid kinase. The presence of SH2 domains within the regulatory subunit suggests a potential association between phosphorylated 2B4 and PI3K. NK cells cultured from healthy individuals were either left inactivated or activated briefly with anti-2B4 and IL-2. Cell lysates were immunoprecipitated with anti-2B4 and immunoblotted with anti-p85. Fig. 2A indicates that the p85 subunit of PI3K associates with 2B4 ~3 min following NK activation and dissociates sometime between 10 and 20 min. The observed association between 2B4 and the p85 subunit of PI3K implies a role for 2B4 in the induction of PI3K activity and the subsequent generation of phosphorylated membrane lipids. To verify that the 2B4·p85 complex has associated enzymatic activity, we immunoprecipitated 2B4·p85 complexes from NK cells before and after 2B4 stimulation and determined the ability of the complexes to generate phospholipid products (Fig. 2B). A lipid substrate (phosphatidylinositol 4,5-bisphosphate) was added to the immunoprecipitated complexes in the presence of [gamma -32P]ATP, and the lipid products were separated by thin layer chromatography and visualized by autoradiography. To determine specifically the role of SAP/SH2D1A in the activation of PI3K, we performed these experiments using normal and XLP-derived NK cells. After 2B4 stimulation, immunoprecipitates derived from normal controls were able to generate phosphoinositide 3' products (phosphatidylinositol 3,4,5-trisphosphate), indicating that PI3K associated with 2B4 is functionally active (Fig. 2B, lane 3). As expected, the addition of wortmannin inhibited this kinase activity (Fig. 2B, lane 2). However, in contrast to cells derived from healthy subjects, immunoprecipitates from NK cells expressing a mutated form of SAP/SH2D1A lacked any PI3K activity (Fig. 2B, lane 6). The loss of PI3K activity was not because of a lack of association between 2B4 and PI3K, although this association was weaker in XLP-derived NK cells (Fig. 2C). We also investigated the effect of PI3K inhibitors, wortmannin or LY294002, on the association of 2B4 with PI3K p85 itself. The pretreatment of NK cells with either inhibitor did not prevent the association of the p85 subunit with 2B4 (Fig. 2D). Therefore, the expression of mutated SAP/SH2D1A alters the association and/or function of PI3K in NK cells, and PI3K activity is absent following 2B4-mediated activation of XLP-derived NK cells.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 2.   2B4 associates with the p85 subunit of PI3K and activated PI3K recruits SAP/SH2D1A to 2B4. A, PI3K associates with 2B4 in activated NK cells. NK cells were incubated in CM alone (lane 1) or with mAb C1.7 and IL-2 for the indicated times (lanes 2-5, respectively) before cell lysis. Lysates were immunoprecipitated (IP) with mAb C1.7 and immunoblotted (IB) with anti-p85 mAb. B, PI3K activity is absent in NK cells carrying a mutation in SAP/SH2D1A. NK cells were isolated and prepared as described above. The cells were treated as indicated, and cell lysates were immunoprecipitated with anti-2B4 and co-incubated with phosphatidylinositol 4,5-bisphosphate in the presence of [gamma -32P]ATP. The arrows indicate either the PI3K products, phosphatidylinositol 1,4,5-trisphosphate (PIP3), or the original spot (Orig.). C, Activated 2B4 recruits PI3K in NK cells of XLP patient. NK cells were incubated as indicated, and cell lysates were immunoprecipitated with anti-2B4 and immunoblotted with anti-p85 mAb. D, the inhibition of PI3K does not prevent association of 2B4 with PI3K. NK cells were treated as indicated. The cells were washed and further incubated for 5 min at 37 °C in CM alone (lane 1) or with mAb C1.7 and IL-2 (lanes 2-5). Cell lysates were immunoprecipitated with mAb C1.7 and immunoblotted with anti-p85 mAb.

Wortmannin Prevents the Association of 2B4 and SAP/SH2D1A-- To investigate further the role of PI3K following 2B4 activation, we studied the effect of wortmannin on the association between 2B4 and SAP/SH2D1A (Fig. 3A). NK cells obtained from healthy individuals were left unstimulated or briefly stimulated with anti-2B4 and IL-2, and the lysates were harvested at 5 min. As expected, because 2B4 is phosphorylated following activation (Fig. 1A), 2B4 and SAP/SH2D1A were associated in stimulated NK cells, however, the pretreatment of cells with PI3K inhibitors but not with other kinase inhibitors resulted in a loss of this association. Because SAP/SH2D1A has previously been shown to associate only with phosphorylated 2B4 (34), we next determined the effect of wortmannin on 2B4 phosphorylation. NK cells from healthy individuals were pretreated with wortmannin and then activated with anti-2B4 to determine whether 2B4 phosphorylation was altered. In normal NK cells, wortmannin did not alter the phosphorylation of 2B4 at 3 min or the dephosphorylation of 2B4 that occurred within 5 min (Fig. 2A). However, in XLP-NK cells, the presence of wortmannin resulted in significantly less phosphorylated 2B4 at both 3 and 5 min, suggesting that dephosphorylation of 2B4 was occurring faster in XLP cells. These observed differences between healthy and XLP NK cells were not because of differences in the phenotype of the cells nor the levels of 2B4 expression (Fig. 3C). Together, these data demonstrate a critical and functional role for PI3K in the recruitment of SAP/SH2D1A to 2B4.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 3.   Wortmannin prevents the association of 2B4 and SAP/SH2D1A. A, inhibition of PI3K prevents the association of 2B4 with SAP/SH2D1A. NK cells were treated as indicated. The cells were washed and further incubated for 5 min at 37 °C in CM (Unstim.) or in CM with mAb C1.7 and IL-2 (Stim.). Cell lysates were immunoprecipitated with anti-2B4 and immunoblotted with anti-SAP/SH2D1A. B, the inhibition of PI3K dephosphorylate-activated 2B4. NK cells were untreated or treated with wortmannin, washed, and further incubated for 3 and 5 min at 37 °C in either CM alone or with mAb C1.7 and IL-2. Cell lysates were immunoprecipitated with anti-2B4 and immunoblotted with antiphosphotyrosine-horseradish peroxidase conjugate (anti-phosphotyrosine). C, phenotype of NK cells. Representative fluorescence-activated cell sorter analysis of NK cells obtained from an XLP patient or from healthy controls. Cells were co-stained with anti-2B4 fluorescein isothiocyanate and anti-CD56 allophycocyanin (APC) (upper panels) or with anti-CD3 fluorescein isothiocyanate and anti-CD56 allophycocyanin (APC) (lower panels) and analyzed by flow cytometry.

NK Cells with a Mutation of SAP/SH2D1A Have Defects in Activation and Cytotoxicity-- In the experiments described above, we determined that the inhibition of PI3K activity prevents an association of SAP/SH2D1A with 2B4, and we showed that NK cells with a mutation of SAP/SH2D1A lack PI3K enzymatic activity. To assess the functional significance of abnormal PI3K signaling, we established NK cytotoxicity assays using cells derived from normal controls and an XLP patient. We showed previously that NK cells carrying the R55L mutation in SAP/SH2D1A have defective cytotoxicity when tested against K562 target cells (23). In those experiments, the reduction of killing by freshly isolated (uncultured) NK cells was a consequence of fewer (CD3-CD56+) NK cells present in XLP males. By using a stringent purification method for selecting NK cells and by culturing them in high dose IL-2, we have since been able to reliably generate CD3-CD56+ NK populations of >90% purity from both healthy volunteers and an XLP patient (Fig. 4A). We compared the cytotoxic function of these effector cells, both normal and XLP-derived, against K562 and Raji targets with or without 2B4 activation. Surprisingly, NK cytotoxicity against K562 cells was not significantly different between the two groups (Fig. 4B), suggesting that IL-2 cultured NK cells from XLP patients are fully capable of killing MHC class I-deficient/low target cells. However, when tested against Raji targets that express surface MHC class I, NK cells from normal controls exhibited more cytotoxicity than XLP NK cells (Fig. 4C, p = 0.002). Moreover, when NK cells were activated with anti-2B4, the differences in cytotoxicity were significantly more apparent against both K562 (Fig. 4D, p < 0.001) and Raji (Fig. 4E, p < 0.0001) cells. These data indicate that XLP-derived NK cells kill MHC class I-deficient target cells in normal fashion but display diminished cytotoxicity against cells expressing MHC class I. In addition, as previously reported, XLP-derived NK cells manifest a significant defect in 2B4-activated cytotoxicity.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 4.   NK cells with a mutation of SAP/SH2D1A have defects in activation and cytotoxicity. A, phenotype of effector cells. Representative immunophenotype of NK cells obtained from an XLP patient or from a healthy control. Cells were co-stained with anti-CD3 fluorescein isothiocyanate and anti-CD56 and analyzed on a FACSCalibur flow cytometer (BD PharMingen) using CellquestTM software. B-E, a comparison of cytotoxicity between normal and XLP-derived NK cells. NK cells from normal donors (n = 6) ( or black-square) or an XLP patient (triangle  or black-triangle) were cultured in CM with 1000 IU/ml IL-2 for 14 days. Cells were washed and incubated in AIM-V medium for 6 h prior to assays. NK cells were incubated in CM alone (B and C) or in CM with mAb C1.7 plus 100 IU/ml IL-2 (D and E), and the NK cytotoxicity was measured in chromium release assays. Target cells used were K562 (B and D) or Raji (C and E). All assays were performed in triplicate and on at least three separate occasions. Each data point is the mean value of the repeated experiments, and the error bars refer to the mean ± S.D. generated from the three independent assays. Student's t test was used to calculate p values. *, p = 0.002; **, p = 0.0006; and ***, p < 0.0001.

Inhibition of PI3K Diminishes the Cytotoxicity of Normal but Not XLP-derived NK Cells-- Using the system noted above, we investigated the effect of PI3K inhibitors on the cytotoxicity of normal and XLP-derived NK cells. NK cells were incubated in the presence or absence of PI3K inhibitors prior to cytotoxicity assays performed with or without 2B4 ligation. We found that both wortmannin and LY294002 significantly reduced the cytotoxicity of normal NK cells against K562 target cells with or without 2B4 activation (Fig. 5, A and C, *, p < 0.0001 in all cases comparing CM alone with wortmannin or LY294002). However, the reduction in cytotoxicity was far less significant in NK cells that carry the XLP mutation (Fig. 5A, **, p = 0.018, and C, **, p = 0.036). Against Raji target cells, normal NK cells were also significantly inhibited by wortmannin or LY294002 (Figs. 5, B and D, *, p < 0.0001 in all cases), but the inhibition of XLP-derived NK cytotoxicity was insignificant (Fig. 5, B, **, p = 0.18, and D, **, p = 0.17). These findings suggest that a mutation of SAP/SH2D1A partially conceals the effect that PI3K inhibitors have on NK cytotoxicity.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 5.   Inhibition of PI3K diminishes the cytotoxicity of normal but not XLP-derived NK cells. The effect of the PI3K inhibition on NK cytotoxicity. NK cells were isolated and prepared as described above. The cells were left untreated (CM) or treated with Lck inhibitor (PP2), wortmannin (Wort), or LY294002 (LY) for 30 min at 37 °C. NK cells were washed and incubated for 5 min in CM (A and B) or CM with C1.7 plus IL-2 (C and D) before NK cytotoxicity was measured in chromium release assays at a 20:1 effector to target ratio. Target cells used were K562 (A and C) or Raji (B and D). All assays were performed in triplicate and on at least three separate occasions. Each data point is the mean value of the repeated experiments, and the error bars refer to the mean ± S.D. generated from the three independent assays. Student's t test was used to calculate p values. *, p < 0.0001 (A-D); **, p = 0.018 (A); **, p < 0.18 (B); **, p = 0.036 (C); **, p = 0.17 (D).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

We have investigated the role of PI3K in 2B4-mediated signal transduction following NK cell activation. In agreement with previous reports (12, 13), we found that 2B4 is phosphorylated ~2 min after 2B4 stimulation, and we showed that phosphorylation of 2B4 is followed first by the association of PI3K at ~3 min and then by the association of SAP/SH2D1A at 5 min. These kinetics of association are consistent with a previous report (34) that SAP/SH2D1A interacts only with the phosphorylated form of 2B4. Interestingly, we found that by inhibiting PI3K activity either with wortmannin or with LY294002, the association of SAP/SH2D1A to 2B4 was prevented, implying that PI3K either directly or indirectly facilitates the binding of SAP/SH2D1A to 2B4. In an XLP patient with an inactivating mutation of SAP/SH2D1A, 2B4 and PI3K continued to be associated (Fig. 2C), but PI3K activity was not present (Fig. 2B), suggesting that conversely PI3K activity is dependent on functioning SAP/SH2D1A. These findings taken together imply a complex sequence of events following 2B4 stimulation where SAP/SH2D1A-2B4 association is dependent on PI3K activity and where PI3K activity is dependent on functional SAP/SH2D1A. These events suggest that SAP/SH2D1A has multiple functions beyond simply binding to phosphorylated 2B4 and may also bind to one or more other phosphotyrosine motifs that facilitate PI3K activity. For instance, it was shown previously that LAT constitutively associates with 2B4, and that the ligation of 2B4 leads to the phosphorylation of LAT and the recruitment of other intracellular proteins to the LAT·2B4 complex (17). It has also been suggested in T cells that the p85 subunit of PI3K associates with LAT directly or with the tyrosine-phosphorylated immunoreceptor tyrosine-based motif of the FcR gamma -chain via the SH2 domains of p85 (35). Thus, SAP/SH2D1A may facilitate PI3K activation through its association with LAT rather than 2B4 (17). Nevertheless, the above findings argue that PI3K plays an important role in mediating the cytotoxicity of 2B4-activated NK cells.

PI3K and its downstream products have been implicated in basic cell processes that influence NK cytotoxicity including chemotaxis (33), trafficking of perforin/granzyme B (29), and plasma membrane reorganization (36). It is unclear as to which of these activities is most important in the context of 2B4-mediated NK cytotoxicity, because all three mechanisms may play critical roles. For example, the recruitment and activation of PI3K may affect NK plasma membrane reorganization. In support of this hypothesis, previous work (37, 38) indicates that CD2, which is closely related to 2B4, assists in adhesion between T cells and antigen-presenting cells, and that the adhesion-promoting properties of CD2 are mediated by the formation of lipid rafts. Raft formation occurred in both activated T cells, a subset of which also express 2B4, (38, 39) and in NK cells (40, 41), and interestingly, it was dependent on PI3K activity (42). Thus, 2B4 stimulation and the downstream functions of both SAP/SH2D1A and PI3K may assist in lipid raft formation, which is critical for signaling and cytotoxicity. In addition, defects of the perforin/granzyme B pathway would certainly affect NK cell cytotoxicity. In this regard, Djeu and colleagues (29, 43) have shown that intracellular redistribution of perforin granules is dependent on PI3K and its downstream effectors, MEK and extracellular signal-regulated kinase-2 (ERK2).

In addition to preventing the association of 2B4 with SAP/SH2D1A, wortmannin and LY294002 were able to inhibit significantly the cytotoxicity of normal NK cells (Fig. 5). This inhibition was much less apparent or absent in NK cells from a patient with XLP, suggesting that a block in signaling at the stage of PI3K was made redundant by a block at the stage of SAP/SH2D1A association. The implication of this redundancy is that PI3K and SAP/SH2D1A participate serially in the same signaling pathway. Therefore, we propose a model whereby the activation of PI3K allows SAP/SH2D1A to associate with 2B4, and we suggest that this association is critical for NK cell effector function. In XLP patients, SAP/SH2D1A is unable to bind to 2B4. Thus, any inhibition of PI3K has no further impact on cytotoxicity, and we conclude that the major effect of wortmannin and LY294002 on blocking cytotoxicity occurs via preventing the association of SAP with 2B4. This conclusion is also consistent with our finding that NK cells carrying mutated SAP/SH2D1A cannot induce PI3K activity following 2B4 stimulation (Fig. 3), although the precise mechanism is unknown.

During investigation of the role of PI3K in NK cytotoxicity, we found as others have (18, 24) that NK cells expressing mutated SAP/SH2D1A lyse K562 target cells as efficiently as normal NK cells. The differences in cytotoxicity between normal and XLP cells only appeared when lymphokine-activated killer-sensitive (NK-resistant) Raji target cells were used or when NK cells were activated with anti-2B4. One difference between K562 cells and Raji cells is that the K562 cells lack or have very low MHC class I surface expression, whereas Raji cells express HLA A, B, C (44). Taken together, one interpretation of these observations is that NK cells from XLP patients are fully capable of killing MHC class I-deficient targets, but because they lack functional SAP/SH2D1A, they are unable to achieve the broader killing repertoire of 2B4-activated NK cells. Because MHC class I-deficient target cells are likely to generate fewer NK inhibitory signals, unstimulated NK cells are still able to efficiently lyse them. We speculate that different viral infections may generate different expression levels of MHC class I on infected cells and that clinically apparent XLP develops only when containment of viral replication requires 2B4-dependent elimination of infected targets.

    ACKNOWLEDGEMENTS

We thank members of the Tan laboratory, especially Erica Lee and Xiaoxia Wang for technical advice and assistance. We also thank Dr. Henry Pabst for providing patient samples and Drs. Mike Gold and C. Bruce Verchere for reviewing the manuscript.

    FOOTNOTES

* This work was supported by the Canadian Institutes of Health Research and the British Columbia's Children's Hospital Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This paper is dedicated to the Kaska people of northwestern Canada.

Dagger Supported by the Michael Smith Foundation for Health Research.

§ To whom correspondence should be addressed: Dept. of Pathology & Laboratory Medicine, BC's Children's Hospital, 4480 Oak St., Rm. 2G5, Vancouver, BC V6H 3V4, Canada. Tel.: 604-875-3605; Fax: 604-875-3777; E-mail: roo@interchange.ubc.ca.

Published, JBC Papers in Press, January 28, 2002, DOI 10.1074/jbc.M112029200

    ABBREVIATIONS

The abbreviations used are: NK, natural killer; SAP/SH2D1A, signaling lymphocytic activation molecule-associated protein; IL-2, interleukin-2; PI3K, phosphoinositide 3-kinase; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; ERK, extracellular signal-regulated kinase; MHC, major histocompatibility complex.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., and Salazar-Mather, T. P. (1999) Annu. Rev. Immunol. 17, 189-220[CrossRef][Medline] [Order article via Infotrieve]
2. Trinchieri, G. (1995) Semin. Immunol. 7, 83-88[CrossRef][Medline] [Order article via Infotrieve]
3. Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., and Moretta, L. (2001) Annu. Rev. Immunol. 19, 197-223[CrossRef][Medline] [Order article via Infotrieve]
4. Lanier, L. L. (1998) Annu. Rev. Immunol. 16, 359-393[CrossRef][Medline] [Order article via Infotrieve]
5. Garni-Wagner, B. A., Purohit, A., Mathew, P. A., Bennett, M., and Kumar, V. (1993) J. Immunol. 151, 60-70[Abstract]
6. Mathew, P. A., Garni-Wagner, B. A., Land, K., Takashima, A., Stoneman, E., Bennett, M., and Kumar, V. (1993) J. Immunol. 151, 5328-5337[Abstract]
7. Nakajima, H., Cella, M., Langen, H., Friedlein, A., and Colonna, M. (1999) Eur. J. Immunol. 29, 1676-1683[CrossRef][Medline] [Order article via Infotrieve]
8. Brown, M. H., Boles, K., van der Merwe, P. A., Kumar, V., Mathew, P. A., and Barclay, A. N. (1998) J. Exp. Med. 188, 2083-2090[Abstract/Free Full Text]
9. Chuang, S. S., Kim, M. H., Johnson, L. A., Albertsson, P., Kitson, R. P., Nannmark, U., Goldfarb, R. H., and Mathew, P. A. (2000) Immunology 100, 378-383[CrossRef][Medline] [Order article via Infotrieve]
10. Stepp, S. E., Schatzle, J. D., Bennett, M., Kumar, V., and Mathew, P. A. (1999) Eur. J. Immunol. 29, 2392-2399[CrossRef][Medline] [Order article via Infotrieve]
11. Nakajima, H., and Colonna, M. (2000) Hum. Immunol. 61, 39-43[CrossRef][Medline] [Order article via Infotrieve]
12. Tangye, S. G., Lazetic, S., Woollatt, E., Sutherland, G. R., Lanier, L. L., and Phillips, J. H. (1999) J. Immunol. 162, 6981-6985[Abstract/Free Full Text]
13. Watzl, C., Stebbins, C. C., and Long, E. O. (2000) J. Immunol. 165, 3545-3548[Abstract/Free Full Text]
14. Bakker, A. B., Wu, J., Phillips, J. H., and Lanier, L. L. (2000) Hum. Immunol. 61, 18-27[CrossRef][Medline] [Order article via Infotrieve]
15. Schatzle, J. D., Sheu, S., Stepp, S. E., Mathew, P. A., Bennett, M., and Kumar, V. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3870-3875[Abstract/Free Full Text]
16. Sylla, B. S., Murphy, K., Cahir-McFarland, E., Lane, W. S., Mosialos, G., and Kieff, E. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 7470-7475[Abstract/Free Full Text]
17. Bottino, C., Augugliaro, R., Castriconi, R., Nanni, M., Biassoni, R., Moretta, L., and Moretta, A. (2000) Eur. J. Immunol. 30, 3718-3722[CrossRef][Medline] [Order article via Infotrieve]
18. Tangye, S. G., Phillips, J. H., Lanier, L. L., and Nichols, K. E. (2000) J. Immunol. 165, 2932-2936[Abstract/Free Full Text]
19. Coffey, A. J., Brooksbank, R. A., Brandau, O., Oohashi, T., Howell, G. R., Bye, J. M., Cahn, A. P., Durham, J., Heath, P., Wray, P., Pavitt, R., Wilkinson, J., Leversha, M., Huckle, E., Shaw-Smith, C. J., Dunham, A., Rhodes, S., Schuster, V., Porta, G., Yin, L., Serafini, P., Sylla, B., Zollo, M., Franco, B., Bentley, D. R., et al.. (1998) Nat. Genet. 20, 129-135[CrossRef][Medline] [Order article via Infotrieve]
20. Sayos, J., Wu, C., Morra, M., Wang, N., Zhang, X., Allen, D., van Schaik, S., Notarangelo, L., Geha, R., Roncarolo, M. G., Oettgen, H., De, Vries, J. E., Aversa, G., and Terhorst, C. (1998) Nature 395, 462-469[CrossRef][Medline] [Order article via Infotrieve]
21. Nichols, K. E., Harkin, D. P., Levitz, S., Krainer, M., Kolquist, K. A., Genovese, C., Bernard, A., Ferguson, M., Zuo, L., Snyder, E., Buckler, A. J., Wise, C., Ashley, J., Lovett, M., Valentine, M. B., Look, A. T., Gerald, W., Housman, D. E., and Haber, D. A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 13765-13770[Abstract/Free Full Text]
22. Parolini, S., Bottino, C., Falco, M., Augugliaro, R., Giliani, S., Franceschini, R., Ochs, H. D., Wolf, H., Bonnefoy, J. Y., Biassoni, R., Moretta, L., Notarangelo, L. D., and Moretta, A. (2000) J. Exp. Med. 192, 337-346[Abstract/Free Full Text]
23. Benoit, L., Wang, X., Pabst, H. F., Dutz, J., and Tan, R. (2000) J. Immunol. 165, 3549-3553[Abstract/Free Full Text]
24. Nakajima, H., Cella, M., Bouchon, A., Grierson, H. L., Lewis, J., Duckett, C. S., Cohen, J. I., and Colonna, M. (2000) Eur. J. Immunol. 30, 3309-3318[CrossRef][Medline] [Order article via Infotrieve]
25. Rameh, L. E., and Cantley, L. C. (1999) J. Biol. Chem. 274, 8347-8350[Free Full Text]
26. Fruman, D. A., Meyers, R. E., and Cantley, L. C. (1998) Annu. Rev. Biochem. 67, 481-507[CrossRef][Medline] [Order article via Infotrieve]
27. Kanakaraj, P., Duckworth, B., Azzoni, L., Kamoun, M., Cantley, L. C., and Perussia, B. (1994) J. Exp. Med. 179, 551-558[Abstract/Free Full Text]
28. Bonnema, J. D., Karnitz, L. M., Schoon, R. A., Abraham, R. T., and Leibson, P. J. (1994) J. Exp. Med. 180, 1427-1435[Abstract/Free Full Text]
29. Jiang, K., Zhong, B., Gilvary, D. L., Corliss, B. C., Hong-Geller, E., Wei, S., and Djeu, J. Y. (2000) Nat. Immunol. 1, 419-425[CrossRef][Medline] [Order article via Infotrieve]
30. al-Aoukaty, A., Rolstad, B., and Maghazachi, A. A. (1999) J. Immunol. 162, 3249-3255[Abstract/Free Full Text]
31. Valiante, N. M., and Trinchieri, G. (1993) J. Exp. Med. 178, 1397-1406[Abstract/Free Full Text]
32. Dutz, J. P., Benoit, L., Wang, X., Demetrick, D. J., Junker, A., de Sa, D., and Tan, R. (2001) Blood 97, 95-100[Abstract/Free Full Text]
33. Servant, G., Weiner, O. D., Herzmark, P., Balla, T., Sedat, J. W., and Bourne, H. R. (2000) Science 287, 1037-1040[Abstract/Free Full Text]
34. Sayos, J., Nguyen, K. B., Wu, C., Stepp, S. E., Howie, D., Schatzle, J. D., Kumar, V., Biron, C. A., and Terhorst, C. (2000) Int. Immunol. 12, 1749-1757[Abstract/Free Full Text]
35. Gibbins, J. M., Briddon, S., Shutes, A., van Vugt, M. J., van de Winkel, J. G., Saito, T., and Watson, S. P. (1998) J. Biol. Chem. 273, 34437-34443[Abstract/Free Full Text]
36. Corvera, S., and Czech, M. P. (1998) Trends Cell Biol. 8, 442-446[CrossRef][Medline] [Order article via Infotrieve]
37. Yashiro-Ohtani, Y., Zhou, X. Y., Toyo-Oka, K., Tai, X. G., Park, C. S., Hamaoka, T., Abe, R., Miyake, K., and Fujiwara, H. (2000) J. Immunol. 164, 1251-1259[Abstract/Free Full Text]
38. Grakoui, A., Bromley, S. K., Sumen, C., Davis, M. M., Shaw, A. S., Allen, P. M., and Dustin, M. L. (1999) Science 285, 221-227[Abstract/Free Full Text]
39. Dustin, M. L., and Shaw, A. S. (1999) Science 283, 649-650[Free Full Text]
40. Davis, D. M., Chiu, I., Fassett, M., Cohen, G. B., Mandelboim, O., and Strominger, J. L. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 15062-15067[Abstract/Free Full Text]
41. Lou, Z., Jevremovic, D., Billadeau, D. D., and Leibson, P. J. (2000) J. Exp. Med. 191, 347-354[Abstract/Free Full Text]
42. Moran, M., and Miceli, M. C. (1998) Immunity 9, 787-796[CrossRef][Medline] [Order article via Infotrieve]
43. Wei, S., Gamero, A. M., Liu, J. H., Daulton, A. A., Valkov, N. I., Trapani, J. A., Larner, A. C., Weber, M. J., and Djeu, J. Y. (1998) J. Exp. Med. 187, 1753-1765[Abstract/Free Full Text]
44. Johnson, D. R. (2000) Hum. Immunol. 61, 389-396[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
J. C. D. Wiseman, L. L. Ma, K. J. Marr, G. J. Jones, and C. H. Mody
Perforin-Dependent Cryptococcal Microbicidal Activity in NK Cells Requires PI3K-Dependent ERK1/2 Signaling
J. Immunol., May 15, 2007; 178(10): 6456 - 6464.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Alvarez-Errico, J. Sayos, and M. Lopez-Botet
The IREM-1 (CD300f) Inhibitory Receptor Associates with the p85{alpha} Subunit of Phosphoinositide 3-Kinase
J. Immunol., January 15, 2007; 178(2): 808 - 816.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Eissmann and C. Watzl
Molecular Analysis of NTB-A Signaling: A Role for EAT-2 in NTB-A-Mediated Activation of Human NK Cells.
J. Immunol., September 1, 2006; 177(5): 3170 - 3177.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
I. Tassi and M. Colonna
The Cytotoxicity Receptor CRACC (CS-1) Recruits EAT-2 and Activates the PI3K and Phospholipase C{gamma} Signaling Pathways in Human NK Cells
J. Immunol., December 15, 2005; 175(12): 7996 - 8002.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Chen, A. K. Tai, M. Lin, F. Chang, C. Terhorst, and B. T. Huber
Signaling Lymphocyte Activation Molecule-Associated Protein Is a Negative Regulator of the CD8 T Cell Response in Mice
J. Immunol., August 15, 2005; 175(4): 2212 - 2218.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Eissmann, L. Beauchamp, J. Wooters, J. C. Tilton, E. O. Long, and C. Watzl
Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244)
Blood, June 15, 2005; 105(12): 4722 - 4729.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Aoukaty and R. Tan
Role for Glycogen Synthase Kinase-3 in NK Cell Cytotoxicity and X-Linked Lymphoproliferative Disease
J. Immunol., April 15, 2005; 174(8): 4551 - 4558.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
R. Chen, F. Relouzat, R. Roncagalli, A. Aoukaty, R. Tan, S. Latour, and A. Veillette
Molecular Dissection of 2B4 Signaling: Implications for Signal Transduction by SLAM-Related Receptors
Mol. Cell. Biol., June 15, 2004; 24(12): 5144 - 5156.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Sanzone, M. Zeyda, M. D. Saemann, M. Soncini, W. Holter, G. Fritsch, W. Knapp, F. Candotti, T. M. Stulnig, and O. Parolini
SLAM-associated Protein Deficiency Causes Imbalanced Early Signal Transduction and Blocks Downstream Activation in T Cells from X-linked Lymphoproliferative Disease Patients
J. Biol. Chem., August 8, 2003; 278(32): 29593 - 29599.
[Abstract] [Full Text] [PDF]


This Article
Right arrow